Analysts predict VK2735 could revolutionize the weight-loss market with its oral administration. Truist maintains a buy rating, praising VK2735's top-tier status. William Blair sees potential for market expansion, impressed by the drug's safety profile. Oppenheimer sees VK2735 as a potential best-in-class due to its efficacy/safety profile.

CNBC’s Jim Cramer on Monday touted the burgeoning bull market of medical devices, noting positive earnings reports from related companies across the board.
“It’s undeniable that we’ve got an emerging bull market in medical devices — we’ve heard the same incredibly positive story from company after company,” Cramer said. “I’m just praying we get another debt ceiling-related sell-off that drags down the entire market and gi...

- INMD did breakout but fell hard and got rejected at the double bottom neckline 35
- With most pennant breakouts, failures will likely return to the medium of the pennant ==> which is around 34
- Significance is 34 is also the MA5/MA20/MA50 level on Daily Chart
- And on the 30mins chart, it is also the same neckline of the possible head and shoulder formation with a breakdown at 34 towards 32.
- As long as it does not break below 32.65, a h...